Abstract
The ATP binding cassette transporter-2 (ABCA2) has been genetically linked to Alzheimers disease but the molecular mechanisms are unknown. In this study, the effects of expression of human ABCA2 on endogenous amyloid precursor protein (APP) expression, trafficking and processing were examined in mouse N2a neuronal cells. ABCA2 expression increased the steady-state APP mRNA levels through transcription. ABCA2 also induced increased synthesis of APP holoprotein and altered APP processing and metabolite generation. ABCA2 expression promoted β-secretase (BACE1) cleavage of APP not at the common Asp1 amino acid site (β-site) of Aβ in APP but at the Glu11 site (β´-site) to increase C89 carboxyl-terminal fragment levels (β´-CTF/C89). The levels of N-terminally truncated Aβ11-40 peptides were also increased by ABCA2 expression. The delivery of newly synthesized APP to the cell surface through the secretary pathway was not perturbed by ABCA2 expression; however, ABCA2 expression increased the amount of APP in earlyendosomal compartments, which also contained the highest levels of β´-CTF/C89 and is likely the site of increased BACE1 processing of APP. This report identifies ABCA2 as a key regulator of endogenous APP expression and processing and suggests a possible biochemical mechanism linking ABCA2 expression, APP processing and Alzheimers disease.
Keywords: ATP-binding cassette transporter, ABCA2, Alzheimer’s, amyloid precursor protein, APP, Glu11 Site, N-terminally truncated Aβ.
Current Alzheimer Research
Title: The ATP-Binding Cassette Transporter-2 (ABCA2) Increases Endogenous Amyloid Precursor Protein Expression and Abeta Fragment Generation
Volume: 7 Issue: 7
Author(s): W. Davis
Affiliation:
Keywords: ATP-binding cassette transporter, ABCA2, Alzheimer’s, amyloid precursor protein, APP, Glu11 Site, N-terminally truncated Aβ.
Abstract: The ATP binding cassette transporter-2 (ABCA2) has been genetically linked to Alzheimers disease but the molecular mechanisms are unknown. In this study, the effects of expression of human ABCA2 on endogenous amyloid precursor protein (APP) expression, trafficking and processing were examined in mouse N2a neuronal cells. ABCA2 expression increased the steady-state APP mRNA levels through transcription. ABCA2 also induced increased synthesis of APP holoprotein and altered APP processing and metabolite generation. ABCA2 expression promoted β-secretase (BACE1) cleavage of APP not at the common Asp1 amino acid site (β-site) of Aβ in APP but at the Glu11 site (β´-site) to increase C89 carboxyl-terminal fragment levels (β´-CTF/C89). The levels of N-terminally truncated Aβ11-40 peptides were also increased by ABCA2 expression. The delivery of newly synthesized APP to the cell surface through the secretary pathway was not perturbed by ABCA2 expression; however, ABCA2 expression increased the amount of APP in earlyendosomal compartments, which also contained the highest levels of β´-CTF/C89 and is likely the site of increased BACE1 processing of APP. This report identifies ABCA2 as a key regulator of endogenous APP expression and processing and suggests a possible biochemical mechanism linking ABCA2 expression, APP processing and Alzheimers disease.
Export Options
About this article
Cite this article as:
Davis W., The ATP-Binding Cassette Transporter-2 (ABCA2) Increases Endogenous Amyloid Precursor Protein Expression and Abeta Fragment Generation, Current Alzheimer Research 2010; 7 (7) . https://dx.doi.org/10.2174/156720510793499002
DOI https://dx.doi.org/10.2174/156720510793499002 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Pharmacoproteomics Studies of Warfarin in the Asia-Pacific: A New Strategy for Personalized Medicine?
Current Pharmacogenomics and Personalized Medicine Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets Ferulic Acid-Loaded Lipid Nanostructures as Drug Delivery Systems for Alzheimers Disease: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides
CNS & Neurological Disorders - Drug Targets Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
Current Neuropharmacology Beneficial Effect of Peptides from Microalgae on Anticancer
Current Protein & Peptide Science The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis
Current Pharmaceutical Design Combination of Hypoxia and RNA-Interference Targeting VEGF Induces Apoptosis in Hepatoma Cells Via Autocrine Mechanisms
Current Pharmaceutical Biotechnology No Significant Effect of 7,8-Dihydroxyflavone on APP Processing and Alzheimer-Associated Phenotypes
Current Alzheimer Research Research Advances in Neuroblastoma Immunotherapy
Current Pediatric Reviews Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Nonsteroidal Anti-Inflammatory Drugs in Experimental Parkinsonian Models and Parkinsons Disease
Current Pharmaceutical Design Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Pathophysiology and Treatment of Diabetic Peripheral Neuropathy: The Case for Diabetic Neurovascular Function as an Essential Component
Current Diabetes Reviews An Update on Adenosine A2A-Dopamine D2 Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors
Current Pharmaceutical Design Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Dissecting the Therapeutic Relevance of Gene Therapy in NeuroAIDS: An Evolving Epidemic
Current Gene Therapy